Downstream Processing in Biopharmaceuticals - Adoption ofDisposable Technology at Improved Economies of Scale toOptimize P...
Scope- A detailed overview of the downstream processing, CMO industry and reagent market.- Annualized market data and fore...
3.1.7 Cell Therapies 113.1.8 Antisense Drugs 113.1.9 Peptide Therapeutics 113.2 Overview of Downstream Processing in Bioph...
8.1 Key Drivers and Restraints 348.1.1 Key Drivers of Downstream Processing Market 348.1.2 Key Restraints of Downstream Pr...
Table 7: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue Forecast($bn), 2011–2018 25Table 8: Downstre...
Figure 12: Downstream Processing, Global, Industry Analysis, Key Drivers and Restraints, 201135Figure 13: Downstream Proce...
Upcoming SlideShare
Loading in …5
×

Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness

195 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
195
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness

  1. 1. Downstream Processing in Biopharmaceuticals - Adoption ofDisposable Technology at Improved Economies of Scale toOptimize Production Efficiency and Cost-effectivenessReport Details:Published:November 2012No. of Pages: 59Price: Single User License – US$3500Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at ImprovedEconomies of Scale to Optimize Production Efficiency and Cost-effectivenessSummaryGBI Research, the leading business intelligence provider, has released its latest research,“Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at ImprovedEconomies of Scale to Optimize Production Efficiency and Cost-effectiveness”, which provides keydata, information and analysis of the Contract Manufacturing Organization (CMO) industry, andthe downstream processing and reagent market. The report provides comprehensive insight intothe size of the CMO market, the downstream processing and reagent market and includesforecasts, key reasons for outsourcing, market characterization, downstream process inbiopharmaceuticals, major reagents, reagent suppliers and the reagent market related todownstream processing, profiles of key equipment players, key reagent players and key CMOplayers, drivers and restraints and deals analysis.This report is built using data and information sourced from proprietary databases, primary andsecondary research and uses in-house analysis from GBI Research’s team of industry experts.Major CMOs offer both upstream and downstream manufacturing functions equally. In addition tomanufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging,and even marketing. According to industry experts, almost 60% of the CMO market in dominatedby manufacturing functions, out of which more than 50% is dominated by the downstreamprocess. GBI research suggests that the CMO market size for downstream processing is set togrow at a Compound Annual Growth Rate (CAGR) of 15.1%, which is more than the growth in theoverall CMO biopharmaceutical market.
  2. 2. Scope- A detailed overview of the downstream processing, CMO industry and reagent market.- Annualized market data and forecasts for the downstream processing, CMO industry andreagent market.- A detailed overview of key reasons behind outsourcing, outsourcing service models and keydrivers and restraints of the market.- A detailed discussion of the downstream processing.- Company profiles of major equipments suppliers, CMOs and reagent players including the keyservices offered by them and their financial information.- Analysis of the Merger and Acquisition (M&A) deals involving key companiesReasons to buy- Develop market-entry and market expansion strategies by identifying areas for high growth andopportunities.- Understand the factors shaping the downstream processing, CMO industry and reagent market.- Identify the top players in the major equipment suppliers, CMO and reagent market, theirfinancial revenues, geographical presence and key services offered.- Analyze the key geographies that are lucrative markets for the downstream processing and aswell as CMOs.- Analyze the trends in licensing and M&A deals and explore potential investment opportunities- Understand upcoming trends that are poised to drive the future growth of the downstreamprocessingGet your copy of this report @http://www.reportsnreports.com/reports/202049-downstream-processing-in-biopharmaceuticals-adoption-of-disposable-technology-at-improved-economies-of-scale-to-optimize-production-efficiency-and-cost-effectiveness.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Downstream Processing in Biopharmaceuticals - Introduction 93 Downstream Processing in Biopharmaceuticals - Market Overview 103.1 Overview of Biopharmaceuticals 103.1.1 Cytokines 103.1.2 Enzymes 103.1.3 Hormones 103.1.4 Clotting Factors 103.1.5 Vaccines 113.1.6 Monoclonal Antibodies 11
  3. 3. 3.1.7 Cell Therapies 113.1.8 Antisense Drugs 113.1.9 Peptide Therapeutics 113.2 Overview of Downstream Processing in Biopharmaceuticals 123.2.1 A Typical Downstream Processing Operation 133.2.2 Major Check Points during Downstream Processing 144 Downstream Processing in Biopharmaceuticals - Role of Downstream Processing in theBiopharmaceutical Industry 154.1 Major Reagents, Reagent Suppliers and Reagents Market related to Downstream Process 184.1.1 Major Reagents 184.1.2 Reagent Suppliers 194.1.3 Reagent Market 214.2 Major Equipment Suppliers 225 Downstream Processing in Biopharmaceuticals - Downstream Processing Market for CMOs 245.1 Global CMO Market Overview 245.2 CMO Biopharmaceuticals Market Characterization 245.3 CMO Market Size for Downstream Processing 266 Downstream Processing in Biopharmaceuticals - Challenges and Unmet Needs in DownstreamBioprocess 286.1 Challenges 286.1.1 Chromatographic Capture 286.1.2 Reducing the Purification Steps 286.1.3 Titer Increment/Capacity Bottleneck 296.1.4 Virus Clearances 296.1.5 Scaling –Up 296.2 Unmet Needs 296.2.1 Unmet Medical Needs 296.2.2 Realistic Achievement of Economies of Scale 296.2.3 Technological Development of Disposables at Large Scale 306.2.4 Reagent Costs and their Effectiveness 307 Downstream Processing in Biopharmaceuticals - Emerging Technologies and their Implications317.1 Single Use Technology/Disposable Technology 327.1.1 Advantages 327.1.2 Disadvantages 327.2 Multi-column Chromatography 327.2.1 Advantages 327.2.2 Disadvantages 337.3 Tangential Flow Filtration 337.3.1 Advantages 337.3.2 Disadvantages 338 Downstream Processing in Biopharmaceuticals - Industry Analysis 34
  4. 4. 8.1 Key Drivers and Restraints 348.1.1 Key Drivers of Downstream Processing Market 348.1.2 Key Restraints of Downstream Processing Market 358.2 Porter’s Five Forces Model for Industry Analysis 368.3 Major Events and their Impact – Analysis 389 Downstream Processing in Biopharmaceuticals - Competitive Landscape 399.1 Market Dynamics of Downstream Processing and Impact 399.1.1 Market Structure 399.2 Key Equipment Players 409.2.1 Pall Corporation 409.2.2 Millipore 429.2.3 Sartorius Stedim Biotech S.A. 449.3 Key Reagent Players 469.3.1 Life Technologies 469.3.2 Sigma Aldrich 489.4 Key CMO Players 509.4.1 Lonza 509.4.2 Boehringer Ingelheim 529.4.3 Diosynth Biotechnology 5410 Downstream Processing in Biopharmaceuticals - Appendix 5610.1 Market Definitions 5610.2 Abbreviations 5610.3 Bibliography 5710.4 Research Methodology 5810.4.1 Coverage 5810.4.2 Secondary Research 5810.4.3 Primary Research 5910.4.4 Expert Panel Validation 5910.5 Contact Us 5910.6 Disclaimer 591.1 List of TablesTable 1: Downstream Processing, Global, Cost Breakups of Upstream and DownstreamProcessing, 2011 17Table 2: Downstream Processing, Global, Reagent Suppliers, 2011 20Table 3: Downstream Processing, Global, Total Reagent Market for Downstream Processing,Revenue ($m), 2009–2011 22Table 4: Downstream Processing, Global, Total Reagent Market for Downstream Processing,Revenue Forecast ($m), 2011–2018 22Table 5: Downstream Processing, Global, Equipment Suppliers, 2011 23Table 6: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue ($bn),2008–2011 25
  5. 5. Table 7: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue Forecast($bn), 2011–2018 25Table 8: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue($bn), 2009–2011 27Table 9: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue($bn), 2011–2018 27Table 10: Downstream Processing, Key Equipment Players, Pall Corporation, Major M&A Deals,2009–2012 41Table 11: Downstream Processing, Key Equipment Players, EMD Millipore, Major M&A Deals,2009–2010 43Table 12: Downstream Processing, Key Equipment Players, Sartorius Stedim Biotech S.A, MajorM&A Deals, 2008 45Table 13: Downstream Processing, Key Reagent Players, Life Technologies, Major M&A Deals,2009–2011 47Table 14: Downstream Processing, Key Reagent Players, Sigma-Aldrich, Major M&A Deals,2009–2012 49Table 15: Downstream Processing, Key CMO Players, Lonza, Major M&A Deals, 2009–2010 51Table 16: Downstream Processing, Key CMO Players, Boehringer Ingelhiem, Major M&A Deals,2009–2011 53Table 17: Downstream Processing, Key CMO Players, Diosynth Biotechnology, Major M&A Deals,2009–2011 551.2 List of FiguresFigure 1: Downstream Processing, Global, Biopharmaceutical Types, 2011 10Figure 2: Downstream Processing, Global, Overview of General Drug Development Process, 201112Figure 3: Downstream Processing, Global, Process Steps, 2011 13Figure 4: Downstream Processing, Global, Changing Distribution of Cost along with YieldIncrement, 2011 15Figure 5: Downstream Processing, Global, Yield Percentage vs Number of Purification Steps,2011 16Figure 6: Downstream Processing, Global, Cost Breakups of Upstream and DownstreamProcessing, 2011 17Figure 7: Downstream Processing, Global, Total Reagent Market for Downstream Processing,Revenue ($m), 2009–2018 21Figure 8: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue ($bn),2008–2018 25Figure 9: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue($bn), 2009–2018 26Figure 10: Downstream Processing, Global, Challenges, 2011 28Figure 11: Downstream Processing, Global, Emerging Technologies and their Likely Adaptation,2011 31
  6. 6. Figure 12: Downstream Processing, Global, Industry Analysis, Key Drivers and Restraints, 201135Figure 13: Downstream Processing, Global, Industry Analysis, Porter’s Five Forces Model, 201136Figure 14: Downstream Processing, Global, Industry Analysis, Major Market Events and theirImpact, 2011 38Figure 15: Downstream Processing, Global, Industry Analysis, Market Dynamics, 2011 39Figure 16: Downstream Processing, Key Equipment Players, Business Overview, PallCorporation, 2011 40Figure 17: Downstream Processing, Key Equipment Players, Business Overview, EMD Millipore,2011 42Figure 18: Downstream Processing, Key Equipment Players, Business Overview, Sartorius StedimBiotech S.A, 2011 44Figure 19: Downstream Processing, Key Reagent Players, Business Overview, Life Technologies,2011 46Figure 20: Downstream Processing, Key Reagent Players, Business Overview, Sigma-Aldrich,2011 48Figure 21: Downstream Processing, Key CMO Players, Business Overview, Lonza, 2011 50Figure 22: Downstream Processing, Key CMO Players, Business Overview, Boehringer Ingelheim,2011 52Figure 23: Downstream Processing, Key CMO Players, Business Overview, DiosynthBiotechnology, 2011 54Contact: sales@reportsandreports.com for more information.

×